Nobody Supports AML Studies Better Than CSI

When it comes to sourcing medicines for Acute Myeloid Leukemia (AML), a supply partner with experience is imperative. At CSI, we’ve built a reputation as a world leader in delivering reliable and timely supply solutions that help drive AML studies forward.

Our expertise spans across numerous global AML programs, partnering with leading pharmaceutical and biotech companies to ensure that clinical trials are never delayed due to supply chain challenges. With direct manufacturer accounts and a fully scientific team, CSI is uniquely positioned to secure the most critical therapies, even when availability is limited.

What sets us apart?

• Proven Track Record: Years of supporting AML studies worldwide, from early-stage trials to late-phase programs.

• Global Reach: Access to key markets and the ability to navigate complex regulatory landscapes with precision.

• Scientific Excellence: Our entire project management team has scientific training, ensuring technical rigor in every study.

• Speed & Reliability: We shorten supply lead times and reduce approval delays, accelerating time to trial.

  
  

At CSI, we know that every AML study carries extraordinary urgency and impact. That’s why we bring the highest level of commitment, knowledge, and execution to every project.

Nobody does AML better than CSI. Don't take our word or it, read our AML supply case study:

Venetoclax and Azacitidine AML Supply